Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 149 of 641 · 7,691 filings

  • Compass Therapeutics (CMPX) FY2025 10-K risk factors
    80 risks2 dropped4 reworded

    Compass Therapeutics shifted its public company status disclosure from emerging growth company to smaller reporting company, detailing specific revenue and non-affiliate share value thresholds.

    Filed Mar 05, 2026
  • Caribou Biosciences (CRBU) FY2025 10-K risk factors
    63 risks5 new8 dropped18 reworded

    Caribou faces Nasdaq delisting risks with its stock price dropping below $1.00.

    Filed Mar 05, 2026
  • CorMedix (CRMD) FY2025 10-K risk factors
    32 risks14 new10 dropped13 reworded

    CorMedix turned profitable in 2025 with $163.1 million in net income, reducing its accumulated deficit to $176.6 million.

    Filed Mar 05, 2026
  • CrowdStrike Holdings (CRWD) FY2026 10-K risk factors
    56 risks1 new2 dropped11 reworded

    July 19 Incident now explicitly linked to deferred or lost purchases, terminated or nonrenewed contracts, and partner reluctance.

    Filed Mar 05, 2026
  • Contineum Therapeutics (CTNM) FY2025 10-K risk factors
    67 risks8 new15 dropped15 reworded

    Contineum Therapeutics highlighted new regulatory hurdles for drug candidates PIPE-791 and PIPE-307.

    Filed Mar 05, 2026
  • Cryoport (CYRX) FY2025 10-K risk factors
    30 risks1 new7 reworded

    Cryoport generated net income of $78.3 million in 2025, reducing its accumulated deficit to $688.9 million. Major insider and 10% stockholder ownership concentration dropped from 71.1% to 23.0%. The company added a dedicated cybersecurity risk disclosure.

    Filed Mar 05, 2026
  • Citizens Community Bancorp (CZWI) FY2025 10-K risk factors
    30 risks1 new1 dropped9 reworded

    Competition risk now covers larger banks and non-depository firms, customer retention, loan and deposit pricing, and service-fee pressure.

    Filed Mar 05, 2026
  • Distribution Solutions Group (DSGR) FY2025 10-K risk factors
    31 risks2 new3 dropped9 reworded

    The company added risks concerning artificial intelligence adoption and tariff uncertainties while updating tax and acquisition figures.

    Filed Mar 05, 2026
  • Entravision Communications (EVC) FY2025 10-K risk factors
    40 risks7 new1 dropped6 reworded

    Entravision added risks concerning AI adoption, mobile gaming reliance, and exposure to a single large Hong Kong customer.

    Filed Mar 05, 2026
  • Evommune (EVMN) FY2025 10-K risk factors
    88 risks

    Evommune faces substantial execution and financing risks to develop and commercialize its lead product candidates EVO756 and EVO301. Clinical trial success, regulatory approvals, and third-party reimbursement are uncertain hurdles for long-term profitability. The company relies heavily on a small team of 48 employees and external contractors.

    Filed Mar 05, 2026
  • EyePoint (EYPT) FY2025 10-K risk factors
    61 risks3 new9 dropped18 reworded

    EyePoint disclosed an agreement in principle to settle a DOJ investigation regarding DEXYCU marketing for $4.7 million plus interest. Competition from better-funded rivals threatens DURAVYU and other commercial products. Manufacturing for YUTIQ remains concentrated in Watertown, Massachusetts.

    Filed Mar 05, 2026
  • Flyexclusive (FLYX) FY2025 10-K risk factors
    68 risks13 new3 dropped15 reworded

    FlyExclusive added disclosures regarding its proposed merger with Jet.AI and related restructuring restrictions.

    Filed Mar 05, 2026

Companies covered

4,011 companies

371 more under A